oasis 1 oral semaglutide 50 mg nejm 2023 obesity Wegovy approved for management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Rybelsus for Weight Loss -

Lixisenatide did not change eGFR decline, and incidences of hard renal endpoints were too low to be meaningfully analyzed [28]

This dual-action approach makes Tirzepatide effective for improving blood sugar control and supporting weight reduction

*Voir selon le poids indiqu sur l'emballage

It is likely that the larger number of statistically significant changes to the microbiome observed in the groups switched from WD to LD reflects their more numerous exposures to different diets, longitudinal changes in dietary exposure, the stress associated with diet switch, the negative energy state achieved by treatment and/or diet-driven weight loss, or a combination of these factors, but it may also be related to differences in terminal body weight and fat mass since both adiposity and diet composition have been shown to modulate the mouse gut microbiome profile

Probiotics Supporting Gut Health and Digestive Comfort Why it matters: GLP-1 medications alter gut motility, which can disrupt the microbiome and trigger symptoms like bloating, diarrhea, and digestive discomfort, particularly in the early weeks of treatment

These concerns can deter them from continuing treatment